Key result
Nisoldipine reduces LV pressure by ~9 mmHg versus placebo while improving regional ejection fraction.
Why the study?
The effects of prolonged nisoldipine administration on chronically underperfused myocardial areas (hibernating myocardium) were not well characterized.
Does prolonged nisoldipine administration improve global and regional left ventricular function in patients with a previous anterior myocardial infarction and hibernating myocardium?
Population
17 patients with previous anterior myocardial infarction, baseline LVEF 34 to 51%, no heart failure
Comparison
Nisoldipine 10 mg twice daily vs placebo
Design
Double-blind randomized controlled trial
Follow-up
2 months
Authors
Loading...
Nisoldipine improves LV function in post-MI hibernating myocardium without HF; extends evidence for dihydropyridine CCBs in stable moderate LV dysfunction.
RCT (n=17)
Double-blind
Does prolonged nisoldipine administration improve global and regional left ventricular function in patients with a previous anterior myocardial infarction and hibernating myocardium?
Absolute Event Rate: -3% vs 6%
p-value: p=<0.01
Prolonged nisoldipine therapy improves systolic and diastolic function specifically in hypokinetic, chronically underperfused myocardial areas without affecting normal myocardium.
Pouleur et al. (1992) conducted an RCT in Previous anterior myocardial infarction with hibernating myocardium (n=17). Nisoldipine vs. Placebo was evaluated on Change in LV systolic and end-diastolic pressure (p=<0.01). Nisoldipine therapy for 2 months significantly lowered LV pressure (-3 vs. +6 mmHg; p<0.01) and improved regional ejection fraction in hypokinetic areas compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: